Minnesota HealthSolutions Corporation — Department of Health and Human Services SBIR Phase II: NHLBI

Minnesota HealthSolutions Corporation — SBIR Phase II award from Department of Health and Human Services.

Phase II SBIR prototype / development signal

  • Phase II is where Department of Health and Human Services funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
  • Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
  • At $1,954,502, this is a large obligation for typical SBIR Phase sizing — worth reviewing for scope breadth and teaming opportunity.
  • Topic code NHLBI links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.

Informational capture context from public federal data — not legal or bid advice.

Amount
$1,954,502
Agency
Department of Health and Human Services · National Institutes of Health
Program / Phase
SBIR · Phase II
Topic
NHLBI
Solicitation
PA20-260
NAICS
Place of performance
MN
Period
2022-02-17 → 2024-01-31

Description

Project Summary/Abstract Minnesota HealthSolutions (MHS) proposes a Phase II project to develop and validate a software product capable of automatically detecting and staging pulmonary embolisms (PEs) using clinically routine pulmonary CT angiograms (CTAs). The proposed system will combine state-of-the-art machine learning methods and the clinical expertise at Duke University into a system that integrates seamlessly into the Radiology workflow and standard patient care path to improve the treatment decisions of physicians in the emergency department. Pulmonary embolism is the third most common cause of death in hospital patients with an estimated incidence of 1 per 1,000 patients. CTAs are routinely used to detect PE today; however, there is significant variability in the detection rate among radiologists using CTA. Furthermore, despite the strong evidence that the RV/LV ratio is an important clinical biomarker it is rarely measured quantitatively in practice. A successful completion of this project would provide a workflow-integrated tool capable of faster PE detection and more accurate staging of right heart strain to guide the physician’s treatment decision.